PCA3

Prostate cancer antigen 3 (PCA3, also referred to as DD3) is a gene that expresses a is_associated_with::non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in is_associated_with::prostate cancer. Because of its restricted expression profile, the PCA3 RNA is useful as a is_associated_with::tumor marker.

Use as biomarker
The most frequently used is_associated_with::biomarker for prostate cancer today is the serum level of is_associated_with::prostate-specific antigen (PSA), or derived measurements. However, since PSA is is_associated_with::prostate-specific but not is_associated_with::cancer-specific, it is an imperfect biomarker. For example, PSA can increase in older men with is_associated_with::benign prostatic hyperplasia. Several new biomarkers are being investigated to improve the diagnosis of prostate cancer. Some of these can be measured in is_associated_with::urine samples, and it is possible that a combination of several urinary biomarkers will replace PSA in the future.

Compared to serum PSA, PCA3 has a lower sensitivity but a higher specificity and a better positive and is_associated_with::negative predictive value. It is independent of prostate volume, whereas PSA is not. It should be measured in the first portion of urine after is_associated_with::prostate massage with is_associated_with::digital rectal examination.

PCA3 has been shown to be useful to predict the presence of malignancy in men undergoing repeat is_associated_with::prostate biopsy. This means that it could be useful clinically for a patient for whom digital rectal examination and PSA suggest possible prostate cancer, but the first prostate biopsy returns a normal result. This occurs in approximately 60% of cases, and on repeat testing, 20-40% have an abnormal biopsy result.

Other uses that are being studied for PCA3 include its correlation with adverse tumor features such as tumor volume, grading (is_associated_with::Gleason score) or extracapsular extension. These studies have so far produced conflicting results.

A commercial kit called the Progensa PCA3 test is marketed by the Californian company is_associated_with::Gen-Probe. Gen-Probe acquired rights to the PCA3 test from is_associated_with::Diagnocure in 2003. Royalties of 16% of cumulative sales of PCA3 kit are paid to Diagnocure. Diagnocure is quoted on TSX as CUR.TO (Canada)

Discovery
PCA3 was discovered to be highly expressed by prostate cancer cells in 1999.